These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33239876)

  • 1. The Challenge of Nanovesicles for Selective Topical Delivery for Acne Treatment: Enhancing Absorption Whilst Avoiding Toxicity.
    Mancuso A; Cristiano MC; Fresta M; Paolino D
    Int J Nanomedicine; 2020; 15():9197-9210. PubMed ID: 33239876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights on the Use of Nanocarriers for Acne Alleviation.
    Amer SS; Nasr M; Mamdouh W; Sammour O
    Curr Drug Deliv; 2019; 16(1):18-25. PubMed ID: 30210000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carrier-based drug delivery system for treatment of acne.
    Vyas A; Kumar Sonker A; Gidwani B
    ScientificWorldJournal; 2014; 2014():276260. PubMed ID: 24688376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drug delivery systems: potential in improving topical delivery of antiacne agents.
    Date AA; Naik B; Nagarsenker MS
    Skin Pharmacol Physiol; 2006; 19(1):2-16. PubMed ID: 16247244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Insights for the Management of Acne in the Modern Era.
    Singh N; Singh A; Pandey K; Nimisha
    Recent Pat Antiinfect Drug Discov; 2020; 15(1):3-29. PubMed ID: 32729430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel topical drug delivery systems and their potential use in acne vulgaris.
    Taglietti M; Hawkins CN; Rao J
    Skin Therapy Lett; 2008 Jun; 13(5):6-8. PubMed ID: 18648713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced skin targeting of retinoic acid spanlastics:
    Shamma RN; Sayed S; Sabry NA; El-Samanoudy SI
    J Liposome Res; 2019 Sep; 29(3):283-290. PubMed ID: 30501429
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical trials in dermatology. Evaluation of the tolerability and efficacy of a topical anti-acne].
    Verschoore M; Poncet M; Schaefer H; Revuz J; De Prost Y; Guillaume JC; Ortonne JP; Czernielewski J
    Therapie; 1991; 46(3):189-91. PubMed ID: 1838841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events related to topical drug treatments for acne vulgaris.
    Otlewska A; Baran W; Batycka-Baran A
    Expert Opin Drug Saf; 2020 Apr; 19(4):513-521. PubMed ID: 32347138
    [No Abstract]   [Full Text] [Related]  

  • 10. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity.
    Raza K; Singh B; Lohan S; Sharma G; Negi P; Yachha Y; Katare OP
    Int J Pharm; 2013 Nov; 456(1):65-72. PubMed ID: 23973754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tazarotene foam, 0.1%, for the treatment of acne.
    Smith JA; Narahari S; Hill D; Feldman SR
    Expert Opin Drug Saf; 2016 Jan; 15(1):99-103. PubMed ID: 26560170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Treatments in Acne Vulgaris: Guidance for the Busy Dermatologist.
    Stein Gold L
    J Drugs Dermatol; 2015 Jun; 14(6):567-72. PubMed ID: 26091381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in polymeric nano-delivery systems targeting hair follicles for the treatment of acne.
    Lei Y; Jiang W; Peng C; Wu D; Wu J; Xu Y; Yan H; Xia X
    Drug Deliv; 2024 Dec; 31(1):2372269. PubMed ID: 38956885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percutaneous absorption and antibacterial activities of lipid nanocarriers loaded with dual drugs for acne treatment.
    Lin CH; Fang YP; Al-Suwayeh SA; Yang SY; Fang JY
    Biol Pharm Bull; 2013; 36(2):276-86. PubMed ID: 23370356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research Techniques Made Simple: Drug Delivery Techniques, Part 1: Concepts in Transepidermal Penetration and Absorption.
    Schmieder S; Patel P; Krishnamurthy K
    J Invest Dermatol; 2015 Nov; 135(11):1-5. PubMed ID: 26548480
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug-cyclodextrin-vesicles dual carrier approach for skin targeting of anti-acne agent.
    Kaur N; Puri R; Jain SK
    AAPS PharmSciTech; 2010 Jun; 11(2):528-37. PubMed ID: 20333488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How patients experience and manage dryness and irritation from acne treatment.
    Feldman SR; Chen DM
    J Drugs Dermatol; 2011 Jun; 10(6):605-8. PubMed ID: 21637901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical therapy for acne vulgaris. How do you choose the best drug for each patient?
    Johnson BA; Nunley JR
    Postgrad Med; 2000 Mar; 107(3):69-70, 73-6, 79-80. PubMed ID: 10728136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acne in the first three decades of life: An update of a disorder with profound implications for all decades of life.
    Greydanus DE; Azmeh R; Cabral MD; Dickson CA; Patel DR
    Dis Mon; 2021 Apr; 67(4):101103. PubMed ID: 33041056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris.
    Marazzi P; Boorman GC; Donald AE; Davies HD
    J Dermatolog Treat; 2002 Sep; 13(3):111-7. PubMed ID: 12227873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.